Volume 387, Issue 10023, Pages 1066-1074 (March 2016) Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial  Prof Jonathan A Ledermann, MD, Andrew C Embleton, MSc, Fharat Raja, BMBCh, Prof Timothy J Perren, MD, Prof Gordon C Jayson, PhD, Prof Gordon J S Rustin, MD, Prof Stan B Kaye, MD, Hal Hirte, MD, Prof Elizabeth Eisenhauer, MD, Michelle Vaughan, MB, Prof Michael Friedlander, MD, Antonio González-Martín, MD, Daniel Stark, MD, Elizabeth Clark, BSc, Laura Farrelly, MSc, Prof Ann Marie Swart, MB, Adrian Cook, MSc, Prof Richard S Kaplan, MD, Prof Mahesh K B Parmar, DPhil  The Lancet  Volume 387, Issue 10023, Pages 1066-1074 (March 2016) DOI: 10.1016/S0140-6736(15)01167-8 Copyright © 2016 Ledermann et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 1 Trial profile SAE=serious adverse events. ITT=intention to treat. ECOG=Eastern Cooperative Oncology Group. The Lancet 2016 387, 1066-1074DOI: (10.1016/S0140-6736(15)01167-8) Copyright © 2016 Ledermann et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 2 Kaplan-Meier plot of progression-free survival over 2 years Vertical reference line shows the median time to completion of the chemotherapy phase. Number at risk every 6 months shown with the number of failure events in parentheses, after the time in which the number at risk was calculated. The Lancet 2016 387, 1066-1074DOI: (10.1016/S0140-6736(15)01167-8) Copyright © 2016 Ledermann et al. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 3 Kaplan-Meier plot of overall survival over 3 years Number at risk every 12 months shown with the number of failure events in parentheses, after the time in which the number at risk was calculated. The Lancet 2016 387, 1066-1074DOI: (10.1016/S0140-6736(15)01167-8) Copyright © 2016 Ledermann et al. Open Access article distributed under the terms of CC BY Terms and Conditions